Deka Biosciences (United States)

Homepage: dekabiosciences.com

Alternate name: Deka Biosciences

ROR: 002w9v046

OpenAlex ID: I4405258084

Federated analysis of autosomal recessive coding variants in 29,745 developmental disorder patients from diverse populations

2024 · V. Kartik Chundru, Zhancheng Zhang, et al. · Nature Genetics · 15

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity

2025 · Julie J. Ahn, Steven Dudics, et al. · Cell Reports Medicine · 11

Phase 1 study of DK2 10 (EGFR), a tumor-targeted IL2 x IL10 dual immunocytokine, in advanced cancer patients: Dose escalation, immune activation, and safety results.

2025 · Alexander I. Spira, Stanley R. Frankel, et al. · Journal of Clinical Oncology · 1

Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.

2024 · Alexander I. Spira, Siqing Fu, et al. · Journal of Clinical Oncology · 1

Designing the Optimal Artificial Immune Synapse: Combining TCEs with Diakines TM (Coupled and Tumor Surface Targeted Cytokines)

2025 · Jacob C. McCright, David P. Langan, et al. · SSRN Electronic Journal

951 Balanced Diakine™ targeted cytokines localize within the immunological synapse and augment immune response in combination with T cell engagers

2024 · Jacob McCright, Steven Dudics, et al. · Journal for ImmunoTherapy of Cancer

43 Immune biomarkers from phase 1 first-in-human trial treating advanced cancer patients with DK210(EGFR) compared to ex vivo DiakineTM response assay

2024 · Abdul Rafeh Naqash, Adanma Ayanambakkam, et al. · Journal for ImmunoTherapy of Cancer

755 DEKA-1 a dose-finding Phase 1 trial: observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors failing systemic therapy

2023 · Alexander I Spira, Douglas Orr, et al. · Journal for ImmunoTherapy of Cancer

718TiP DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy

2023 · E. Moser, M. Salkeni, et al. · Annals of Oncology

Works count: 9

Citation count: 287